SCYNEXIS, Inc. (SCYX) |
| 4.11 -0.28 (-6.38%) 09-16 16:00 |
| Open: | 4.43 |
| High: | 4.525 |
| Low: | 4.08 |
| Volume: | 102,683 |
| Market Cap: | 26(M) |
| PE Ratio: | -1.2 |
| Exchange: | NASDAQ |
| Industry: | Medical - Pharmaceuticals |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.09 |
| Resistance 1: | 5.32 |
| Pivot price: | 5.04 |
| Support 1: | 4.08 |
| Support 2: | 3.39 |
| 52w High: | 9.2 |
| 52w Low: | 3.53 |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -74.595 |
| Profit Margin (%) | -53.26 |
| Operating Margin (%) | -3.00 |
| Return on Assets (ttm) | 308.5 |
| Return on Equity (ttm) | -20.8 |
Company news
Tue, 15 Sep 2026
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
Fri, 11 Sep 2026
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
Fri, 11 Sep 2026
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
Fri, 11 Sep 2026
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
Fri, 11 Sep 2026
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
Wed, 09 Sep 2026
Scynexis Appoints New CFO Amid Transition - Intellectia AI
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
